Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The pharmacokinetics and safety of ritonavir-boosted indinavir 600/100mg bid combined with NRTIs [nucleoside reverse transcriptase inhibitors] in ARV [antiretroviral therapy] naive HIV/TB [HIV/tuberculosis] co-infected patients receiving rifampicin containing anti-tuberculosis therapy

Next Previous
Trial Profile

The pharmacokinetics and safety of ritonavir-boosted indinavir 600/100mg bid combined with NRTIs [nucleoside reverse transcriptase inhibitors] in ARV [antiretroviral therapy] naive HIV/TB [HIV/tuberculosis] co-infected patients receiving rifampicin containing anti-tuberculosis therapy

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Indinavir (Primary) ; Ritonavir (Primary) ; Antituberculars; Nucleoside reverse transcriptase inhibitors; Rifampicin
  • Indications HIV infections; Tuberculosis
  • Focus Pharmacokinetics

Most Recent Events

  • 04 Jun 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
  • 04 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 24 Mar 2009 Planned end date changed from 1 Dec 2007 to 1 Jun 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top